Ascentage Pharma Group International
AAPG Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$15.44
KIRA · Stoqly’s AI analyst, in plain words
- Ascentage Pharma Group International had $79.9M of revenue in fiscal 2025, down 41.4% on the year before.
- Ascentage Pharma Group International lost $173M in fiscal 2025.
- Free cash flow was −$167M in fiscal 2025, −209.3% of revenue.
- Ascentage Pharma Group International returned $1.3M to shareholders in fiscal 2025. The diluted share count rose 17.9%.
- Ascentage Pharma Group International owes $112M more than it holds in cash.
Market cap
$1.4B
P/E
—
Revenue
$79.9M
Net income
−$173M
Free cash flow
−$167M
Operating margin
—
Ascentage Pharma Group International in 30 seconds · fiscal 2025
Are sales growing?
−41.4%
No. Sales fell 41.4% last year.
Does it make a profit?
−216.5%
No. It lost money last year.
Does profit turn into cash?
−209.3%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Ascentage Pharma Group International does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 29, 2026
- Legal name
- ASCENTAGE PHARMA GROUP INTERNATIONAL
- CIK
- 0002023311
Ascentage Pharma Group International · AAPG
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $31.1M | $31.3M | $136M | $79.9M |
| Revenue growth | — | 0.6% | 334.8% | −41.4% |
| Gross margin | 89.5% | 86.2% | 97.0% | 91.5% |
| Net income | −$131M | −$131M | −$56.3M | −$173M |
| Net margin | −421.0% | −417.0% | −41.3% | −216.5% |
| Diluted EPS | −$1.99 | −$1.85 | −$0.74 | −$1.94 |
| Cash | ||||
| Cash from operations | −$97.1M | −$103M | −$15.5M | −$163M |
| Capital expenditure | $30.2M | $6.5M | $3.4M | $3.8M |
| Free cash flow | −$127M | −$109M | −$18.8M | −$167M |
| FCF margin | −408.8% | −347.9% | −13.8% | −209.3% |
| Share buybacks | $4.0M | $0.8M | — | $1.3M |
| Share count change | — | 7.1% | 7.0% | 17.9% |
| Debt and strength | ||||
| Cash and short-term investments | $195M | $146M | $122M | $171M |
| Debt incl. finance leases | — | $253M | $229M | $283M |
| Shareholders' equity | $59.2M | $8.5M | $36.2M | $189M |
| Current ratio | — | 1.4x | 1.3x | 1.8x |
| Returns and quality | ||||
| Return on equity | −221.4% | −385.8% | −252.1% | −153.4% |
| Return on tangible equity | −221.4% | −2,599.1% | −171.7% | −93.1% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ascentage Pharma Group International · AAPG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $15.44 a share, the company is worth $1.4B.
Source: SEC EDGAR XBRL filings (CIK 0002023311). Data updated October 24, 2026. Filed in CNY under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.